GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Unearned Premiums

Sagimet Biosciences (STU:0O2) Unearned Premiums


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Unearned Premiums?

Unearned Premiums only applies to insurance companies.


Sagimet Biosciences Business Description

Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).